

DAFTAR PUSTAKA

1. Zou Z, Liu G, Hay SI, Basu S, Belgaumi UI, Dhali A, et al. Time Trends in Tuberculosis Mortality Across The BRICS : an Age Peroid Cohort Analysis for The GBD 2019. *eClinicalMedicine*. 2022.
2. Ranzani OT, Rodrigues LC, Bombarda S, Minto CM, Waldman EA, Carvalho CRR. Long-Term Survival and Cause-Specific Mortality of Patients Newly Diagnosed With Tuberculosis in Sao Paulo State, Brazil, 2010-15: a Population-based, Longitudinal Study. 2019.
3. WHO.INT. World Health Organization. [Online].; 2022 [cited 2022 November Senin. Available from: <https://www.who.int/es/news/item/27-10-2022-tuberculosis-deaths-and-disease-increase-during-the-covid-19-pandemic>.
4. Kemenkes. Kementerian Kesehatan Republik Indonesia. [Online].; 2022 [cited 2022 September Minggu. Available from: <https://www.kemkes.go.id/article/view/22032300001/tahun-ini-kemenkes-rencanakan-skrining-tbc-besar-besaran.html>.
5. Delgado KC, Bravo SG, Montag AR, Ortiz AB. Mortality among MDR-TB Cases Comparison with Drug-Susceptible Tuberculosis and Associated Factors. *Plos One*. 2015.
6. Indonesia T. TBC Indonesia. [Online].; 2022 [cited 2022 November Selasa. Available from: <https://tbindonesia.or.id/pustaka-tbc/dashboard-tb/>.
7. Indonesia T. TBC Indonesia. [Online].; 2022 [cited 2022 November Selasa. Available from: <https://tbindonesia.or.id/pustaka-tbc/dashboard-tb/>.
8. Indonesia T. TBC Indonesia. [Online].; 2022 [cited 2022 November Selasa. Available from: <https://tbindonesia.or.id/pustaka-tbc/dashboard-tb/>.
9. Ahdiat A. Katadata Media Network. [Online].; 2022 [cited 2022 November Rabu. Available from: <https://databoks.katadata.co.id/datapublish/2022/08/23/ini-provinsi-dengan-kasus-tbc-terbanyak-pada-2021>.
10. Reviono , Kusnanto P, Eko V, Pakiding H, Nurwidiasih D. Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis. *MKB*. 2014.

11. Ratnasari NY. Faktor Risiko Kejadian Multi Drug Resistant Tuberculosis (MDR TB) di Surakarta, Jawa Tengah. *Jurnal Penelitian Kesehatan Suara Forikes*. 2020;; p. 2086-3098.
12. Safaev K, Parpeiva N, Liverko I, Yuldashev S, Dumchev K, Gadoev J, et al. Trends, Characteristics and Treatment Outcomes of Patients With Drug-Resistant Tuberculosis in Uzbekistan: 2013-2018. *International Journal of Environmental Research and Public Health*. 2021.
13. Balabanova Y, Ignatyeva O, Fiebig L, Riekstina V, Danilovits M, Jaama K, et al. Survival of Patients With Multidrug-resistant TB in Eastern Europe: What Makes a Difference. 2016;; p. 2015-207638.
14. Machmud PB, Gayatri D, Ronoatmojo S. A Survival Analysis of Successful and Poor Treatment Outcomes Among Patient With Multidrug-resistant Tuberculosis and the Associated Factors: A Retrospective Cohort Study. *Indonesia Journal International Med*. 2021.
15. Montes K, Atluri H, Tuch HS, Ramirez L, Paiz J, Lopez AH, et al. Risk factors for mortality and multidrug resistance in pulmonary tuberculosis in Guatemala: A retrospective analysis of mandatory reporting. *Journal of Clinical Tuberculosis and Other Mycobacterial Disease*. 2021;; p. 2405-5794.
16. Moosazadeh M, Bahrampour A, Nasehi M, Khanjani N. Survival and Predictors of Death After Successful Treatment Among Smear Positive Tuberculosis: A Cohort Study. *International Journal of Preventive Medicine*. 2014.
17. Utara DKPS. Dinas Kesehatan Provinsi Sumatera Utara. [Online]. Medan; 2022 [cited 2023 Maret Sabtu. Available from: <https://dinkes.sumutprov.go.id/search/unduh?keyword=PROFIL%20KESEHATAN>.
18. Jali MV, Kavital A, Hiremath MB. Challenges of Diabetes in Elderly TB Patients. *Indian Journal of Tuberculosis* 69. 2022;; p. S264-S266.
19. Burhan E, Soepandi PZ, Isbaniah F, Damayanti K, Edwar SQ, Maruli MF, et al. Determinants of Treatment Outcomes in Patients With Multidrug-resistant TB. *The International Journal of Tuberculosis and Lung Disease*. 2022;; p. 126-132.
20. Wang JJ, Zhou ML, Chen C, Wu G, Zuo YP, Ren X, et al. Survival Time and Influencing Factors in Multidrug-resistant Tuberculosis Patients in Wuhan

2006-2014. National Library of Medicine. 2019;; p. 1409-1413.

21. Bisson GP, Bastos M, Campbell JR, Bang D, Brust JC, Isaakadis P, et al. Mortality in Adult With Multidrug-resistant Tuberculosis and HIV by Antiretriviral Therapy and Tuberculosis Drug Use : an Individual Patient Data Meta-analysis. *Lancet*. 2020;; p. 402-11.
22. Martin-Iguacel R, Llibre JM, Pedersen C, Obel N, Staerke NB, Ashberg J, et al. Tuberculosis Incidence and Mortality in People Living With Human Immunodeficiency Virus : a Danish Nationwide Cohort Study. *Clinical Microbiology and Infection*. 2022;; p. 570-579.
23. Girum T, Tariku Y, Dessu S. Survival Status and Treatmen Outcome of Multidrug-Resisntant Tuberculosis (MDR-TB) Among Patients Treated in Treatment Initiation Centers (TIC) in South Ethiopia : A Restrospective Cohort Study. 2017.
24. Firnawati AF. Ketahanan Hidup 2 Tahun Pasien Tuberkulosis Resisten Obat Di RS. Moewardi Surakarta Tahun 2010 - 2014. 2017; 33(8).
25. Ayuningsih Z, Wahyono TYM. Faktor yang Berhubungan dengan Kematian Pasien TB MDR Selama Masa Pengobatan di Indonesia Tahun 2015-2017. *Pro Health Jurnal Ilmiah Kesehatan*. 2019;; p. 41-47.
26. Hulu VT, Supinganto A, Khariri LA, Sianturi E, Nilasari , Siagian N, et al. Eoidemiologi Penyakit Menular: Riwayat, Penularan dan Pencegahan: Yayasan Kita Menulis; 2020.
27. Handayani I, Sumarni. Tuberkulosis: Penerbit NEM; 2021.
28. Koupael M, Naimi A, Moafi N, Mohammadi P, Tabatabaei FS, Ghazizhadeh S, et al. Clinical Characteristics, Diagnosis, Treatment, and Mortality Rate of TBCOVID-19 Coinfectetd Patients A Systematic Review. *Frontiers in Medicine*. 2021.
29. Santos DTD, Alves LS, Arcoverde MAM, Arroyo LH, Berra TZ, Ramos ACV, et al. Social Risk and its Association with Tuberculosis Mortality in a Context of High Inequality in South Brazil : A Geo-Epidemiology Analysis. *Journal of Infection and Public Health*. 2020;; p. 1184-1155.
30. Kemenkes. Kementerian Kesehatan Republik Indonesia. [Online].; 2021 [cited 2022 September Minggu. Available from: <https://www.kemkes.go.id/article/view/21032500001/jadikan-penerus->

[bangsa-bebas-tbc-dimulai-dari-diri-sendiri-dan-keluarga.html](https://www.kemkes.go.id/article/view/20032500003/pasien-tbc-harus-lebih-waspada-corona.html).

31. Dewi BDN. Diabetes Mellitus & Infeksi Tuberkulosis Yogyakarta: ANDI; 2019.
32. Kemenkes. Kementerian Kesehatan Republik Indonesia. [Online].; 2020 [cited 2022 September Minggu. Available from: <https://www.kemkes.go.id/article/view/20032500003/pasien-tbc-harus-lebih-waspada-corona.html>.
33. Kemenkes. Kementerian Kesehatan Republik Indonesia. [Online].; 2022 [cited 2022 September Minggu. Available from: <https://www.kemkes.go.id/article/view/22021400003/tidak-semua-orang-terinfeksi-kuman-tbc-mengalami-gejala-sakit.html>.
34. Indonesia T. TBC Indonesia. [Online].; 2022 [cited 2022 November Selasa. Available from: <https://tbindonesia.or.id/pustaka-tbc/informasi/tentang-tbc/apa-itu-tbc/>.
35. Pralambang SD, Setiawan S. Faktor Risiko Kejadian Tuberkulosis di Indonesia. Jurnal BIKFOKES. 2021.
36. Pangaribuan L, Kristina , Perwitasari D, Tejayanti T, Lolong DB. Faktor-faktor yang Mempengaruhi Kejadian Tuberkulosis pada Umur 15 Tahun ke atas di Indonesia (Analisis Data Survei Prevalensi Tuberkulosis (SPTB) di Indonesia 2013-2014). Puslitbang Upaya Kesehatan Masyarakat. 2020.
37. Janan M. Faktor-faktor Risiko yang Berhubungan Dengan Peningkatan Prevalensi Kejadian TB-MDR di Kabupaten Brebes Tahun 2011-2017. Jurnal Kebijakan Kesehatan indonesia : JKKI. 2019;; p. 64-70.
38. Indonesia T. TBC Indonesia. [Online].; 2021 [cited 2022 November Selasa. Available from: <https://tbindonesia.or.id/pustaka-tbc/informasi/teknis/tb-mdr/>.
39. Indonesia T. TBC Indonesia. [Online].; 2021 [cited 2022 November Selasa. Available from: <https://tbindonesia.or.id/pustaka-tbc/informasi/tentang-tbc/sejarah-tbc-di-indonesia/>.
40. Kemenkes. Kementerian Kesehatan Republik Indonesia. [Online].; 2021 [cited 2022 September Minggu. Available from: <https://www.kemkes.go.id/article/view/21032400001/cara-sama-tanggulangi-tbc-dan-covid-19.html>.

41. Bade AB, Mega TA. Survival Status and its Predictors Among Multi-drug Resistance Tuberculosis Treated Patients in Ethiopia: Multicenter Observational Study. PLOS. 2020.
42. Shimbire MS, Degaga TS, Hebo SH, Zerdo Z, Girum T, Teshome T. Survival and Predictors of Mortality From Multidrug-resistant Tuberculosis (MDR-TB) Among Patients Treated at MDR-TB Referah Hospitals in European: A Retrospective Cohort Study. Journal of Public Health and Epidemiology. 2020;; p. 13-21.
43. Rasyid R. Analisis Faktor Determinan Tuberkulosis Paru Padang: Andalas University Press; 2014.
44. Olaleya AO, Beke AK. Survival of Smear-positive Multidrug-resistant Tuberculosis Patients in Witbank South Africa: A Retrospective Cohort Study. Infectious Disease. 2016;; p. 2374-4243.
45. Wang XH, Ma AG, Han XX, Liang H, Wang D, Schouten E, et al. Survival and Associated Mortality Risk Factors Among Post-Treatment Pulmonary Tuberculosis Patients in The Northwest of China. European Review for Medicine and Pharmacological Sciences. 2015.
46. Korua ES, Kapantow NH, Kawatu PAT. Hubungan Antara Umur, Jenis Kelamin dan Kepadatan Hunian dengan Kejadian TB Paru pada Pasien Rawat Jalan di Rumah Sakit Umum Daerah Noongan. 2015.
47. Santos DTd, al e. Survival Time Among Patients Who Were Diagnosed With Tuberculosis, The Precocious Deaths and Associated Factors in Southern Brazil. Tropical Medicine and Health. 2021.
48. Tatar D, Senol G, Kirakli C, Edipoglu O, Cimen P. Contributing Factors to Mortality Rates of Pulmonary Tuberculosis in Intensive Care Units. Journal of the Chinese Medical Association. 2018;; p. 605-610.
49. Muluneh MA, Zeru AB, Deresh BT, Kebede AM. Survival Status and Predictors of Mortality Among Multidrug-resistant Tuberculosis Patients in Saint Peter's Specialized Hospital, Addis Ababa, Ethiopia. Canadian Journal of Infectious Disease and Medical Microbiology. 2021;; p. 9.
50. Yaghi AR, Shaheed HS, Harun SN, Ali IAH, Khan AH. Survival Trend of Tuberculosis Patients and Risk Factors Associated With Mortality and Developing Drug-Resistant Tuberculosis in Hospital Pulau Pinang Malaysia: A Retrospective Study. Advances in Respiratory Medicine. 2022;; p. 467-

51. Menkes. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. In Indonesia MKR. Keputusan Menteri Kesehatan Republik Indonesia. Jakarta; 2019.
52. Feltrin AFDS, Vendrammini SHF, Neto FC, Correa APdV, Werneck AL, Geraldes NS, et al. Death in Pasien With Tuberculosis and Diabetes : Associated Factors. *Diabetes Research and Clinical Practice*. 2016.
53. Magee MJ, Foote M, Maggio DM, Howards PP, Narayan KV, Blumberg HM, et al. Diabetes Mellitus and Risk of All-Case Mortality Among Patients With Tuberculosis in the State of Georgia, 2009-2012. *Annals of Epidemiology*. 2014.
54. Dahlan MS. Analisis Survival: Dasar-dasar Teori dan Aplikasi Program Stata. 2nd ed. Riefmanto , editor. Jakarta: Sagung Seto; 2014.
55. Sutrisna M, Rahmadani E. Hubungan Usia dan Jenis Kelamin dengan TB-MDR. *SEHATRAKYAT(Jurnal Kesehatan Masyarakat)*. 2022 November; 1(4).
56. Sudargo T, Aristasari T, 'Afifah A, Prameswari AA, Ratri FA, Putri SR. Asuhan Gizi Pada Lanjut Usia Ratri FA, Aristasari T, 'Afifah A, Prameswari AA, editors. Yogyakarta: Gadjah Mada University Press; 2021.
57. Woya AA, Tekile AK, Basha GW. Spatial Frailty Survival Model for Multidrug-Resistant Tuberculosis Mortality in Amhara Region, Ethiopia. *Hindawi Tuberculosis Research and Treatment*. 2019;(7).
58. Irwan. Etika Dasar Perilaku Kesehatan. 1st ed. Yogyakarta: CV.ABSOLUTE MEDIA; 2017.
59. Mertaniasih NM, Koendhori EB, Kusumaningrum D. Buku Ajar Tuberculosis Diagnostik Mikrobiologis. 1st ed. Mertaniasih NM, Koendhori EB, Kusumaningrum D, editors. Surabaya: Pusat Penerbitan dan Percetakan Unair(AUP); 2013.
60. Wang J, Zhou M, Chen Z, Chen C, Wu G, Zou Y, et al. Survival of Patients With Multidrug-resistant Tuberculosis in Central China: a Retrospective Cohort Study. Cambridge University Press. 2020.
61. Nurrahma M. Hubungan Keterlambatan Pengobatan Pasien Tuberculosis

Resisten Obat dengan Kualitas Hidup di RSUP Dr. Moewardi. 2022.

62. Junus AJ. Survival TB Resisten Obat dan Model Kepatuhan Pengobatan Dengan Pendekatan Motivational Interviewing Terhadap Pengendalian Lost to Follow up Pasien TB Resisten Obat Makassar; 2018.
63. Devi AU, Cahyo K, Shaluhayah Z. Faktor-faktor Yang Berhubungan Dengan Perilaku Pasien TB MDR Dalam Pencegahan Penularan TB MDR di Wilayah Kerja Puskesmas Kota Semarang. *Jurnal Kesehatan Masyarakat*. 2019 Januari; 7(1).
64. Kuncoromurti PW. Determinan Keterlambatan Diagnosis dan Terapi Tuberkulosis Multidrug-Resistant di Fasilitas Kesehatan Surakarta: UPT Perpustakaan Universitas Sebelas Maret; 2018.
65. Ngabonziza J, Habimana Y, Decroo T, Migambi P, Dushime A, Mazarati J, et al. Reduction of Diagnostic and Treatment Delays Reduces Rifampicin-resistant Tuberculosis Mortality in Rwanda. *The International Journal of Tuberculosis and Lung Disease*. 2020 Maret; 24(3).
66. Suyanto D, Sariningsih L, Andriyoko B, Santoso P. Pelacakan Pasien TB MDR Terkonfirmasi Yang Belum Memulai Pengobatan di RSUP Dr. Hasan Sadikin Bandung Periode April 2012 - Februari 2015. *Indonesian Journal Chest & Critical Care Medicine*. 2017 Januari-Maret; 4(1).
67. Cunha R, Maruza M, Montarroyos U, Coimbra I, Mirananda-Filho DdB, Albuquerque MdF, et al. Survival of People Living With HIV Who Defaulted From Tuberculosis Treatment in a Cohort, Recife, Brazil. *BMC Infectious Disease*. 2017;(17:137).
68. WHO.INT. Global Tuberculosis Report 2022. ; 2022.
69. Barria RM. Cohort Studies in Health Science London, United Kingdom: IntechOpen; 2018.
70. Bukundi EM, Mhimbira F, Kishimba R, Kondo Z, Moshiro C. Mortality and Associated Factors Among Adult Patients on Tuberculosis Treatment in Tanzania A Retrospective Cohort Study. *Journal of Clinical Tuberculosis and Other Mycobacterium Disease*. 2021.
71. Priyastama R. SPSS Pengolahan & Analisis Data Yogyakarta: Penerbit Anak Hebat Indonesia; 2020.

72. Alobu I, Oshi SN, Oshi DC, Ukwaja KN. Risk Factors of Treatment Default and Death Among Tuberculosis Patients in a Resource-Limited Setting. *Asian Pacific Journal of Tropical Medicine*. 2014;; p. 977-984.
73. Brust JCM, Shah NS, Mlisana K, Moodley P, Allana S, Campbell A, et al. Improved Survival and Cure Rates With Consurent Treatment for Multidrug-resistant Tuberculosis-Human Immunodeficiency Virus Coinfections in South Africa. *Clinical Infectious Disease Major Article*. 2018.
74. Tohardi A. *Pengantar Metodologi Penelitian Sosial + Plus Tanjungpura*: Tanjungpura University Press; 2019.

